According to reports, pharmaceutical company Eli Lilly is moving research funding from UC San Diego to USC in order to test an experimental Alzheimer’s drug, which is a disappointment for San Diego in its efforts for controlling the disease project.

UC San Diego is having an official fight with USC over management of the Alzheimer’s Disease Cooperative Study, which is a countrywide project of clinical trials intended to come up with better diagnosis and treatment of the neurodegenerative condition.

Lawsuits have been filed by the schools that are known throughout the world in field of academic, research and business circles.

According to Lilly, it will shift an unrevealed amount of money that it had thought of giving to UC San Diego for further testing of solanezumab that could prove helpful for patients who show signs of Alzheimer’s disease, however don’t show any external symptoms.

The study that is called A4, is related to the Alzheimer’s project, which UC San Diego has controlled for nearly 24 years. The project is a public-private partnership backed by the National Institutes of Health, Lilly and philanthropic organizations.

According to the company, “From the outset of this unfortunate dispute, Lilly has publicly stated that the company’s objectives are to maintain the safety of the A4 participants, ensure scientific and data integrity for the study and maintain our obligations as the regulatory sponsor”.

The company added that it found that it is interested in the A4 study, following a careful assessment of the continuing situation.